Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study-Reference-Cited by-同舟云学术

Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study

Published:2017-01-26 Issue:3 Volume:35 Page:269-276
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Takahara Naminatsu,Isayama Hiroyuki,Nakai Yousuke,Sasaki Takashi,Ishigaki Kazunaga,Saito Kei,Akiyama Dai,Uchino Rie,Mizuno Suguru,Yagioka Hiroshi,Kogure Hirofumi,Togawa Osamu,Matsubara Saburo,Ito Yukiko,Toda Nobuo,Tada Minoru,Koike Kazuhiko

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/article/10.1007/s10637-017-0430-7/fulltext.html

Reference20 articles.

1. Miyakawa S, Ishihara S, Horiguchi A et al (2009) Biliary tract cancer treatment: 5,584 results from the biliary tract cancer statistics registry from 1998 to 2004 in Japan. J Hepato-Biliary-Pancreat Surg 16:1–7

2. Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281

3. Okusaka T, Nakachi K, Fukutomi A et al (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103:469–474

4. Furuse J, Okusaka T, Boku N et al (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62:849–855

5. Sasaki T, Isayama H, Yashima Y et al (2009) S-1 monotherapy in patients with advanced biliary tract cancer. Oncology 77:71–74

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Body mass index and survival among patients with advanced biliary tract cancer: a single-institutional study with nationwide data-based validation;Journal of Gastroenterology;2024-06-19

2. Lenvatinib plus PD-1 inhibitors combined with chemotherapy versus lenvatinib plus PD-1 inhibitors for unresectable or recurrent biliary tract cancer;2023-06-30

3. Development of a model based on the age-adjusted Charlson comorbidity index to predict survival for resected perihilar cholangiocarcinoma;World Journal of Gastrointestinal Oncology;2023-06-15

4. Prevalence of acute oral mucosal damage secondary to the use of systemic antineoplastics: A systematic review and meta-analysis;Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology;2023-03

5. A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer;Investigational New Drugs;2022-12-02